with Frank Lee
Frank Lee, Executive Chairman of Therini Bio, will discuss Therini’s work developing a drug aimed at targeting brain inflammation to treat Alzheimer’s disease. Lee has over 30 years of global experience in product development and commercial leadership both in small biotech and large pharma. Therini is developing a drug to block the protein fibrin from causing inflammation without affecting its essential blood clotting function. The ADDF is currently funding a phase 1 clinical trial for Therini’s drug.
Presented by The Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
Alzheimer’s Disease affects more than 50 million people and is the only top 10 cause of death that cannot yet be “prevented, treated or cured.” “Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s and other dementias. This series invites three top investigators to share the latest updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to developing therapeutics and biomarkers that prevent, treat, and cure Alzheimer’s and related dementias.
